Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Circulation Year : 2003

Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.


BACKGROUND: Intravitreal neovascular diseases, as in ischemic retinopathies, are a major cause of blindness. Because inflammatory mechanisms influence vitreal neovascularization and cyclooxygenase (COX)-2 promotes tumor angiogenesis, we investigated the role of COX-2 in ischemic proliferative retinopathy. METHODS AND RESULTS: We describe here that COX-2 is induced in retinal astrocytes in human diabetic retinopathy, in the murine and rat model of ischemic proliferative retinopathy in vivo, and in hypoxic astrocytes in vitro. Specific COX-2 but not COX-1 inhibitors prevented intravitreal neovascularization, whereas prostaglandin E2, mainly via its prostaglandin E receptor 3 (EP3), exacerbated neovascularization. COX-2 inhibition induced an upregulation of thrombospondin-1 and its CD36 receptor, consistent with the observed antiangiogenic effects of COX-2 inhibition; EP3 stimulation reversed effects of COX-2 inhibitors on thrombospondin-1 and CD36. CONCLUSIONS: These findings point to an important role for COX-2 in ischemic proliferative retinopathy, as in diabetes.
Fichier principal
Vignette du fichier
Circ03.pdf (494.69 Ko) Télécharger le fichier

Dates and versions

inserm-00150824 , version 1 (15-01-2010)



Florian Sennlaub, Fatemeh Valamanesh, Alejandro Vazquez-Tello, Ahmed M. El-Asrar, Daniella Checchin, et al.. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.. Circulation, 2003, 108 (2), pp.198-204. ⟨10.1161/01.CIR.0000080735.93327.00⟩. ⟨inserm-00150824⟩


192 View
286 Download



Gmail Facebook X LinkedIn More